Biological behavior of magnesium-substituted hydroxyapatite during bone repair / Comportamento biológico de hidroxiapatita substituída com magnésio durante o reparo ósseo

Abstract The aim of this study was to analyze the biological behavior and osteogenic potential of magnesium (Mg) substituted hydroxyapatite (HA) microspheres, implanted in a critical bone defect, considering that this ion is of great clinical interest, since it is closely associated with homeostasis and bone mineralization. For the purpose of this study, 30 rats were used to compose three experimental groups: GI - bone defect filled with HA microspheres; GII - bone defect filled with HA microspheres replaced with Mg; GIII - empty bone defect; evaluated at biological points of 15 and 45 days. The histological results, at 15 days, showed, in all the groups, a discrete chronic inflammatory infiltrate; biomaterials intact and surrounded by connective tissue; and bone neoformation restricted to the borders. At 45 days, in the GI and GII groups, an inflammatory response of discrete granulomatous chronic type was observed, and in the GIII there was a scarce presence of mononuclear inflammatory cells; in GI and GII, the microspheres were seen to be either intact or fragmented, surrounded by fibrous connective tissue rich in blood vessels; and discrete bone neoformation near the edges and surrounding some microspheres. In GIII, the mineralization was limited to the borders and the remaining area was filled by fibrous connective tissue. It was concluded that the biomaterials were biocompatible and osteoconductive, and the percentage of Mg used as replacement ion in the HA did not favor a greater bone neoformation in relation to the HA without the metal.

Resumo O objetivo deste estudo foi analisar o comportamento biológico de microesferas de hidroxiapatita (HA) substituída com magnésio (Mg) durante o reparo de defeito ósseo crítico, tendo em vista que este íon é de grande interesse clínico, pois está intimamente associado à homeostasia e à mineralização óssea. Para tanto, utilizou-se 30 ratos para compor três grupos experimentais: GI - defeito ósseo preenchido com microesferas de HA; GII - defeito ósseo preenchido com microesferas de HA substituída com Mg; GIII (controle) - defeito ósseo vazio; avaliados nos pontos biológicos de 15 e 45 dias. Os resultados histológicos evidenciaram, aos 15 dias, discreto infiltrado inflamatório crônico e neoformação óssea restrita às bordas, em todos os grupos. Nos grupos GI e GII, os biomateriais mantiveram-se íntegros e circundados por tecido conjuntivo frouxo. Aos 45 dias, notou-se resposta inflamatória do tipo crônica granulomatosa discreta nos grupos GI e GII, e no GIII presença escassa de células inflamatórias mononucleares. As microesferas implantadas no GI e GII mantiveram-se, em sua maioria, íntegras e envolvidas por tecido conjuntivo fibroso. Notou-se discreta neoformação óssea próxima às bordas e circunjacente a algumas microesferas. No GIII, a mineralização limitou-se às bordas e a área remanescente foi preenchida por tecido conjuntivo fibroso. Conclui-se que os biomateriais foram biocompatíveis, bioativos, osteocondutores e apresentaram biodegradação lenta, indicando seu grande potencial para em aplicações clínica como biomaterial de preenchimento.

Biological behavior of magnesium-substituted hydroxyapatite during bone repair

Abstract The aim of this study was to analyze the biological behavior and osteogenic potential of magnesium (Mg) substituted hydroxyapatite (HA) microspheres, implanted in a critical bone defect, considering that this ion is of great clinical interest, since it is closely associated with homeostasis and bone mineralization. For the purpose of this study, 30 rats were used to compose three experimental groups: GI - bone defect filled with HA microspheres; GII - bone defect filled with HA microspheres replaced with Mg; GIII - empty bone defect; evaluated at biological points of 15 and 45 days. The histological results, at 15 days, showed, in all the groups, a discrete chronic inflammatory infiltrate; biomaterials intact and surrounded by connective tissue; and bone neoformation restricted to the borders. At 45 days, in the GI and GII groups, an inflammatory response of discrete granulomatous chronic type was observed, and in the GIII there was a scarce presence of mononuclear inflammatory cells; in GI and GII, the microspheres were seen to be either intact or fragmented, surrounded by fibrous connective tissue rich in blood vessels; and discrete bone neoformation near the edges and surrounding some microspheres. In GIII, the mineralization was limited to the borders and the remaining area was filled by fibrous connective tissue. It was concluded that the biomaterials were biocompatible and osteoconductive, and the percentage of Mg used as replacement ion in the HA did not favor a greater bone neoformation in relation to the HA without the metal.

Resumo O objetivo deste estudo foi analisar o comportamento biológico de microesferas de hidroxiapatita (HA) substituída com magnésio (Mg) durante o reparo de defeito ósseo crítico, tendo em vista que este íon é de grande interesse clínico, pois está intimamente associado à homeostasia e à mineralização óssea. Para tanto, utilizou-se 30 ratos para compor três grupos experimentais: GI - defeito ósseo preenchido com microesferas de HA; GII - defeito ósseo preenchido com microesferas de HA substituída com Mg; GIII (controle) - defeito ósseo vazio; avaliados nos pontos biológicos de 15 e 45 dias. Os resultados histológicos evidenciaram, aos 15 dias, discreto infiltrado inflamatório crônico e neoformação óssea restrita às bordas, em todos os grupos. Nos grupos GI e GII, os biomateriais mantiveram-se íntegros e circundados por tecido conjuntivo frouxo. Aos 45 dias, notou-se resposta inflamatória do tipo crônica granulomatosa discreta nos grupos GI e GII, e no GIII presença escassa de células inflamatórias mononucleares. As microesferas implantadas no GI e GII mantiveram-se, em sua maioria, íntegras e envolvidas por tecido conjuntivo fibroso. Notou-se discreta neoformação óssea próxima às bordas e circunjacente a algumas microesferas. No GIII, a mineralização limitou-se às bordas e a área remanescente foi preenchida por tecido conjuntivo fibroso. Conclui-se que os biomateriais foram biocompatíveis, bioativos, osteocondutores e apresentaram biodegradação lenta, indicando seu grande potencial para em aplicações clínica como biomaterial de preenchimento.

Genetic population structure of an anchialine shrimp, Metabetaeus lohena (Crustacea: Alpheidae), in the Hawaiian Islands

Anchialine habitats in the Hawaiian Islands, characterized as coastal bodies of land-locked salt or brackish water that fluctuate with the tides due to subterranean connections, are the only ecosystems of this type found within the United States. These habitats are currently subject to anthropogenic impacts tha t threaten their future existence. Previous research has shown strong genetic population structure of an endemic atyid shrimp, Halocaridina rubra, in these habitats. The native alpheid shrimp, Metabetaeus lohena, whose known range entirely overlaps that of H. rubra, has feeding and reproductive behaviors that are biologically distinct from H. rubra. Its historic scarcity and status as a candidate for the US Fish and Wildlife Department’s Endangered Species List, make M. lohena an ideal species to compare against the known genetic structure of H. rubra. We investigated the population structure of this native anchialine shrimp to test the hypothesis that genetic population structure differs between the two shrimp species and that M. lohena is genetically unstructured across its range. A survey of 605 bp of the mitochondrial cytochrome c oxidase subunit I (COI) gene from 127 individuals collected at 7 sites spanning the islands of O’ahu, Maui and Hawaii revealed 43 haplotypes. The most common haplotype was represented in similar proportions from all sites sampled, accounting for 44% of the surveyed sequences. Analyses of molecular variation (AMOVA), pairwise ΦST values, Bayesian estimates of migration (M), Mantel tests and Nested Clade Analyses (NCAs) all failed to reveal evidence of major barriers to gene flow among most populations separated by inter-island channels. This lack of genetic structure in M. lohena is found to be in stark contrast with the highly structured population of H. rubra, and may be attributed to oceanic dispersal strategies and/or a recent introduction to the Hawaiian Islands. Rev. Biol. Trop. 58 (1): 159-170. Epub 2010 March 01.

Los hábitats de los alfeidos de las islas de Hawaii, se caracterizan por ser zonas cerradas de aguas saladas o salobres, que fluctúan con las mareas, debido a las conexiones subterráneas, son los únicos ecosistemas de este tipo que se encuentran en Estados Unidos. Estos hábitats actualmente están sujetos a impactos antropogénicos que amenazan su existencia futura. La investigación anterior ha demostrado una fuerte estructura genética de una población de camarones atíidos endémicos, Halocaridina rubra, en estos hábitats. El camarón alfeido nativo, Metabetaeus lohena, cuya área de distribución conocida se superpone totalmente con la de H. rubra, tiene comportamientos alimenticios y reproductivos que son biológicamente diferentes a los de H. rubra. Su escasez histórica y su condición de candidato para aparecer en la Lista de Especies en Peligro del Departamento de Pesca y Vida Silvestre de Estados Unidos, hace de M. lohena una especie ideal para comparar su estructura genética con la de H. rubra. Se investigó la estructura de la población de este camarón alfeido nativo para probar la hipótesis que la estructura genética de la población difiere entre las dos especies y que la de M. lohena está genéticamente no estructurada en todo su ámbito. El análisis de 605 pb de la oxidasa mitocondrial citocromo c subunidad I (COI) de genes de 127 individuos recolectados en 7 sitios que abarcan las islas de Oahu, Maui y Hawaii reveló 43 haplotipos. El haplotipo más común fue representado en proporciones similares en todos los sitios incluidos en la muestra, de acuerdo al 44% de las secuencias estudiadas. El análisis de variación molecular (AMOVA), los valores de ΦST pareados, la estimación bayesiana de la migración (M), las pruebas de Mantel y los Análisis Cladísticos no pudieron revelar la existencia de importantes barreras al flujo genético entre las poblaciones más separadas por los canales entre las islas. La falta de estructura genética en M. lohena contrasta con la muy estructurada población de H. rubra, y puede ser atribuida a las estrategias de dispersión oceánica y/o una introducción reciente en las islas hawaianas.

Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol

The pharmacokinetics of some β-blockers are altered by cardiopulmonary bypass (CPB). The objective of this study was to compare the effect of coronary artery bypass graft (CABG) surgery employing CPB on the pharmacokinetics of propranolol and atenolol. We studied patients receiving oral propranolol with doses ranging from 80 to 240 mg (N = 11) or atenolol with doses ranging from 25 to 100 mg (N = 8) in the pre- and postoperative period of CABG with moderately hypothermic CPB (32°C). On the day before and on the first day after surgery, blood samples were collected before β-blocker administration and every 2 h thereafter. Plasma levels were determined using high-performance liquid chromatography and data were treated by pharmacokinetics-modelling. Statistical analysis was performed using ANOVA or the Friedman test, as appropriate, and P < 0.05 was considered to be significant. A prolongation of propranolol biological half-life from 5.41 ± 0.75 to 11.46 ± 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 ± 2.83 to 19.33 ± 6.52 L/kg (P = 0.0032) were observed after CABG with CPB. No significant changes were observed in either atenolol biological half-life (from 11.20 ± 1.60 to 11.44 ± 2.89 h) or atenolol volume of distribution (from 2.90 ± 0.36 to 3.83 ± 0.72 L/kg). Total clearance was not changed by surgery. These CPB-induced alterations in propranolol pharmacokinetics may promote unexpected long-lasting effects in the postoperative period while the effects of atenolol were not modified by CPB surgery.

Primary culture of the region of the amebocyte-producing organ of the snail Biomphalaria glabrata, the intermediate host of Schistosoma mansoni

Biomphalaria glabrata snails are major hosts for the digenetic trematoda Schistosoma mansoni, the causative agent of human schistosomiasis. The success or failure of the infection will be dependent on the mobilization of the molluskan internal defense system, where a major role will be played by circulating hemocytes produced by the APO (amebocyte-producing organ) of the snail. In this report, the primary culture of the APO region of B. glabrata was obtained for the first time, as well as a control culture of the ovotestis. Three different cell populations migrated easily from the explants in culture, with no need of any dispersion agent. The cells grew in suspension at an incubation temperature of 15°C and the cultures were maintained viable for up to two weeks. Two of these cell populations obtained resembled cell types known to be present in the hemolymph of Biomphalaria. The availability of APO cells in culture may contribute to a better understanding of the internal defense in mollusks, in general, as well as the specific response of B. glabrata to S. mansoni infection.

Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery

The pharmacokinetics of propranolol may be altered by hypothermic cardiopulmonary bypass (CPB), resulting in unpredictable postoperative hemodynamic responses to usual doses. The objective of the present study was to investigate the pharmacokinetics of propranolol in patients undergoing coronary artery bypass grafting (CABG) by CPB under moderate hypothermia. We evaluated 11 patients, 4 women and 7 men (mean age 57 ± 8 years, mean weight 75.4 ± 11.9 kg and mean body surface area 1.83 ± 0.19 m²), receiving propranolol before surgery (80-240 mg a day) and postoperatively (10 mg a day). Plasma propranolol levels were measured before and after CPB by high-performance liquid chromatography. Pharmacokinetic Solutions 2.0 software was used to estimate the pharmacokinetic parameters after administration of the drug pre- and postoperatively. There was an increase of biological half-life from 4.5 (95 percent CI = 3.9-6.9) to 10.6 h (95 percent CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95 percent CI = 3.2-14.3) to 8.3 l/kg (95 percent CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95 percent CI = 7.7-24.6) vs 10.7 ml min-1 kg-1 (95 percent CI = 7.7-26.6; NS) after surgery. In conclusion, increases in drug distribution could be explained in part by hemodilution during CPB. On the other hand, the increase of biological half-life can be attributed to changes in hepatic metabolism induced by CPB under moderate hypothermia. These alterations in the pharmacokinetics of propranolol after CABG with hypothermic CPB might induce a greater myocardial depression in response to propranolol than would be expected with an equivalent dose during the postoperative period.

A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography

We describe a new simple, selective and sensitive micromethod based on HPLC and fluorescence detection to measure debrisoquine (D) and 4-hydroxydebrisoquine (4-OHD) in urine for the investigation of xenobiotic metabolism by debrisoquine hydroxylase (CYP2D6). Four hundred µl of urine was required for the analysis of D and 4-OHD. Peaks were eluted at 8.3 min (4-OHD), 14.0 min (D) and 16.6 min for the internal standard, metoprolol (20 µg/ml). The 5-µm CN-reverse-phase column (Shimpack, 250 x 4.6 mm) was eluted with a mobile phase consisting of 0.25 M acetate buffer, pH 5.0, and acetonitrile (9:1, v/v) at 0.7 ml/min with detection at lexcitation = 210 nm and lemission = 290 nm. The method, validated on the basis of measurements of spiked urine, presented 3 ng/ml (D) and 6 ng/ml (4-OHD) sensitivity, 390-6240 ng/ml (D) and 750-12000 ng/ml (4-OHD) linearity, and 5.7/8.2 percent (D) and 5.3/8.2 percent (4-OHD) intra/interassay precision. The method was validated using urine of a healthy Caucasian volunteer who received one 10-mg tablet of Declinax®, po, in the morning after an overnight fast. Urine samples (diuresis of 4 or 6 h) were collected from zero to 24 h. The urinary excretion of D and 4-OHD, Fel (0-24 h), i.e., fraction of dose administered and excreted into urine, was 6.4 percent and 31.9 percent, respectively. The hydroxylation capacity index reported as metabolic ratio was 0.18 (D/4-OHD) for the person investigated and can be compared to reference limits of < 12.5 for poor metabolizers (PM) and < 12.5 for extensive metabolizers (EM). In parallel, the recovery ratio (RR), another hydroxylation capacity index, was 0.85 (4-OHD: SD + 4-OHD) versus reference limits of RR < 0.12 for PM and RR > 0.12 for EM. The healthy volunteer was considered to be an extensive metabolizer on the basis of the debrisoquine test.

Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability

The bioavailability of propranolol depends on the degree of liver metabolism. Orally but not intravenously administered propranolol is heavily metabolized. In the present study we assessed the pharmacokinetics and pharmacodynamics of sublingual propranolol. Fourteen severely hypertensive patients (diastolic blood pressure (DBP) =115 mmHg), aged 40 to 66 years, were randomly chosen to receive a single dose of 40 mg propranolol hydrochloride by sublingual or peroral administration. Systolic (SBP) and diastolic (DBP) blood pressures, heart rate (HR) for pharmacodynamics and blood samples for noncompartmental pharmacokinetics were obtained at baseline and at 10,20,30,60 and 120 min after the single dose. Significant reductions in BP and HR were obtained, but differences in these parameters were not observed when sublingual and peroral administrations were compared as follows: SBP (17 vs 18 percent, P=NS), DBP (14 vs 8 percent, P=NS) and HR (22 vs 28 percent, P=NS), respectively. The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 + 72 vs 41 + 12 nl/ml, P<0.05; time to reach CMAX (TMAX): 34 + 18 vs 52 + 11 min, P<0.05; biological hall-life (t1/2b): 0.91 + 0.54 vs 2.41 + 1.16 h, P<0.05; area under the curve (AUCT): 245 + 134 vs 79 + 54 ng h(-1) ml(-1), P<0.05; total body clearance (CLT/F):44 + 23 vs 26 + 12 ml min(-1) kg(-1), P=NS. Systemic availability measured by the AUCT ratio indicates that extension of bioavailability was increased 3 times by the sublingual route. Mouth paresthesia was the main adverse effect observed after sublingual administration. Sublingual propranolol administration showed a better pharmacokinetic profile and this route of administration may be an alternative for intravenous or oral administration.

Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass

Twenty-four surgical patients of both sexes without cardiac, hepatic, renal or endocrine dysfunctions were divided into two groups: 10 cardiac surgical patients submitted to myocardial revascularization and cardiopulmonary bypass (CPB), 3 females and 7 males aged 65 ñ 11 years, 74 ñ 16 kg body weight, 166 ñ 9 cm height and 1.80 ñ 0.2l m2 body surface area (BSA), and control, 14 surgical patients not submitted to CPB, 11 female and 3 males aged 41 ñ 14 years, 66 ñ 14 kg body weight, 159 ñ 9 cm height and 1.65 ñ 0.16 m2 BSA (mean ñ SD). Sodium diclofenac (1 mg/kg, im Voltaren 75( twice a day) was administered to patients in the Recovery Unit 48 h after surgery. Venous blood samples were collected during a period of 0-12 h and analgesia was measured by the visual analogue scale(VAS) during the same period. Plasma diclofenac levels were measured by high performance liquid chromatography. A two-compartment open model was applied to obtain the plasma decay curve and to estimate kinetic parameters. Plasma diclofenac protein binding decreased whereas free plasma diclofenac levels were increased five-fold in CPB patients. Data obtained for analgesia reported as the maximum effect (EMA were: 25 per cent VAS (CPB) vs 1O per cent VAS (control), P<0.05, median measured by the visual analogue scale where lOO per cent is equivalent to the highest level of pain. To correlate the effect versus plasma diclofen levels, the EMAX sigmoid model was applied. A prolongation of the mean residence time for maximum effect (MRTEMAX) was observed without any change in lag-time in CPB in spite of the reduced analgesia reported for these patients, during the time-dose interval. In conclusion, the extent of plasma diclofenac protein binding was influenced by CPB with clinicall relevant kinetic-dynamic consequences.

A simple and sensitive high-performance liquid chromatographic method to measure antipyrine and its metabolites in human urine

A method which permits the simultaneous HPLC analysis of antipyrine (A), 3-hydroxymethylantipyrine (HMA), 4-hydroxyantipyrine (HOA) and norantiopyrine (NORA) using a single extraction step in a five minute chromatographic run is described. Only 500 micraLitro of urine were necessary for the quantitation of all compounds investigated. An analog derivative, 4-aminoantipyrine, was used as internal standard (IS). Urine samples were hydrolyzed with Limpet acetone powder, 37 graus centigrados, pH 5.0 for 2 h. Sodium chloride was added and urine samples were extracted with diclhormethane-isopropyl alcohol (90:10, v/v) in acidic medium. The residue was dissolved with mobile phase, washed with n-hexane and 20 micralitro of the lower phase were injected into a 4-micron Nova-Pak (R) 'C IND. 18' column. Peaks monitored at 254 nm were eluted with 0.75 M sodium acetate buffer, pH 5.0: methanol, (70:30, v/v) as mobile phase. The method, validated on the basis of the confidence limits for antipyrine and its metabolites, presented good stability, sensitivity, linearity, and intra or interassay precisions lower than 5 percente for all commpounds were investigated. This assay was applied for drug metabolism study carried out in ten healthy volunteers: 23 about 5 yr and 63 about 10 kg(mean about SD) after p.o. single dose of antipyrine, 500 mg/capsule. Diuresis of 24 h up to 72 h of drug administration was preserved with sodium metabisulfite, 4 mg/mL. Biological fluids were stored at -20 centigrade degree until assay. The main hydroxy-metabolites (HMA + HOA) and NORA, minor N-demethylated metabolite of antipyrine, were excreted: 60 percent and 20 percente as percentage of the given dose, respectively. Clearances for production of metabolites expressed as mL/min, were: 8.61 about 4.28 (7.24) for HMA, 13.91 about 6.20(12.67) for HOA, and 8.08 about 4.01(5.93) for NORA, mean about SD (median).

Tumor venéreo transmissível (TVT) extragenital em cäo. Relato de caso / Extragenital transmissible venereal tumor in a dog. Case report

This report describes a case of cutaneous transmissible veneral tumor (TVT) in a three-year-old male mongrel dog. Through clinical examination it was observed several cutaneous nodule ranging from aproximately 5mm to 4cm in diameter, some of which ulcerated, and several small and ulcerated nodules on the mucous membrane of the mouth. Through the Fine Meedle Aspiration (FNA) technique, the material of cutaneous nodules was sampled and processed for citologic and karyotypic exams. Upon citology, there was abundance of cells with round nuclei with coarsely granular chromatin and single distinct nucleoli, and cytoplasm containing several vacuoles. The karyotype showed a number of 58 chromosomes. Based on cytological and karyotypic findings extragenital TVT was diagnosed. The dog was treated with vincristine sulfate (Oncovin) in a dose of 0,025 mg/kg/weekly/IV. After the second aplication there was a reduction of 80 per cent of nodules with a complete cure at the end of the treatment

HTLV-I/II as a common etiology of myelopathies in Bahia, Brazil

Infection by human T-cell lymphotrophic virus type I (HTLV-I) is associated with a myelopathy known as tropical spastic paraparesis (TSP). The prevalence of HTLV-I infection was found to be high in a pilot study in Bahia, Brazil. In the present study, among patients with myleopathy of unclear etiology, 27 per cent (17/62) were immunoblot reactive to HTLV-I/II (serum and CSF), but none of 40 consecutive patients seen at the neurological clinic and having a well-established neurological diagnosis had detectable antibodies against those viruses (discrimination between HTLV-I and HTLV-II was not possible with the tests we used). The clinical syndrome of typical TSP with upper limb hyperreflexia was found to be a significant feature among the HTLV-I/II-seropositive patients compared to seronegative individuals. The 17 HTLV-I/II-reactive individuals had negative tests for syphilis, toxoplasmosis and schistosomiasis. TSP was also associated with female gender (P=0.001). We conclude that TSP is strongly associated with HTLV-I/II infection in women in Bahia.

Theophylline-ranitidine interaction in elderly COPD patients

Most controlled studies in humans indicate that ranitidine does not alter theophylline metabolism, even at high doses. However, there have been several case reports published recently which demostrate the development of theophylline toxicity mostly in older patients receiving stable oral doses of this drug when ranitidine was administered simultaneously. We studied eleven elderly (mean age, 69,0 + or - 6.2 years) patients with chronic obstructive pulmonary disease (COPD). During one week the patients took slow-release theophylline, 200 mg every 12 h, followed by one week intake of the same dose of theophylline plus ranitidine tables, 150 mg every 12h. At the end of each period, blood samples were obtained 0,1,2,3,4,6,7,8 and 12h after the morning dose for the determination of serum theophylline levels. the peak theophylline concentration was achieved after 4.1 + or - 0.9 h while the patients were taking theophylline, and after 2.9 + or - 1.4 h with the combined regimen. This difference was statistically significant. These results suggest that the reported increases in serum theophylline levels in older patients receiving theophylline and ranitidine cannot be ascribed to slower theophylline metabolism in the geriatric patient with COPD who is also given ranitidine.

Prevalência de discinesia tardia em pacientes internados nos hospitais psiquiátricos de Salvador, Bahia, Brasil / Prevalence of tardive dyskinesia on hospitalized patients in psychiatric hospitals from Salvador, Bahia, Brazil

Os autores apresentam estudo transversal da prevalência da discinesia tardia (DT) em pacientes internados em unidades psiquiátricas da cidade de Salvador durante o mês de setembro-1992. Após revisäo da literatura, comentam a prevalência média de DT encontrada: 1,65 por cento na populaçäo de 2115 pacientes, usando protocolo baseado na escala de Simpson

Simplified micromethod for the HPLC measurement of diclofenac in plasma

A simple and senmsitive micromethod based on HPLC is described for the measurement of diclofenac in 200 ul plasma. A single extraction with dichlormethane in acidic medium was an essential clean-up step. Diclofenac and its internal standard (cyclohexendiphenyl propionic acid) were eluted at 3.3 and 6.5 min from a 4-micron C18 reverse-phase column using a mobile phase consisting of 0.75 M sodium acetate buffer, pH 5.0, and acetonitrile (55:45, v/v) at a flow rate of 0.9 ml/min with detection at 282 nm. The method, validated on the basis of parameters evaluated nfor the confidence limits of diclofenac measurements in spiked plasma, presented 1 ng/ml sensitivity, 10-10,000 ng/ml linearity, and 3.5% and 5.7% intra-and interassay precision, respectively. Peak plasma diclofenac levels ranging from 177 to 841 ng/ml and from 276 to 1008 ng/ml were obtained for two slow-release formulations. A wide range (1 ng/ml-3 ug/ml) was observed for plasma diclofenac levels of volunteers during a 24-h study period

Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension

In a randomized placebo-controlled study, 12 hypertensive patients were treated po for one week with 20 mg nitrendipine once daily plus placebo, twice daily and later with the same dose of nitrendipine plus 300 mg ranitidine (150 mg twice a day). When ranitidine was coadministered, plasma nitrendipine levels (0-24 h) were significantly increased (P<0.001),although no significant increase in peak plasma nitrendipine level (C max) was observed due to the wide range of variation of this parameter (C max) in hypertensive patients. Ranitidine coadministration increased the area under the curve for 24-h (AUC 0-24) plasma concentration vs time, from 49.07 ñ 6.28 ug h/l to 82.35 ñ 2.57 ug h/l (P<0.01). This significant increase caused a reduction in total body clearance from 20008.33 ñ 246.33 to 1284.00 ñ 182.16 ml/min (P<0.002). Nitrendipine bioavailability weas increased by 89% when ranitidine was coadministered but the kinetic effect of this drug interaction is unikely to be of clinical relevance since no adverse effects were observed in patients evaluated after ranitidine association

Influencia da associacao teofilina e beta-2-agonista por via oral, na funcao pulmonar de pacientes portadores de doenca pulmonar obstrutiva cronica / Influence of the combination of theophylline and beta 2 agonists by oral route on pulmonary function of patients with chronic obstructive lung disease

A eficacia da associacao de teofilina e agentes beta-adrenergicos na terapeutica da obstrucao bronquica e tema controverso na literatura. Com este objetivo, foram estudados nove pacientes portadores de DPOC, com idades entre 51 e 69 (media de 60,6 ñ 6,6) anos, nos quais foi comparada a funcao pulmonar com o uso de teofilina isolada ou combinada ao salbutamol, por via oral. Apos a suspensao de qualquer medicacao broncodilatadora por 24 horas foram determinados os valores basais da capacidade vital forcada (CVF) e do volume expiratorio forcado no primeiro segundo "(VEF IND. 1)". Teofilina de acao prolongada (600mg/dia) foi, entao, administrada por via oral por sete dias, seguidos de sete dias de ingestao oral na mesma dose de teofilina associada a 16mg/dia de salbutamol. Os parametros espirometricos foram analisados ao final de cada semana. A CVF basal foi de 0,85 e 2,57 (media 1,78 ñ 0,64) litros, o "VEF IND. 1" 0,70 a 164 (medida 1,15 ñ 0,30) litros e a teofinemia 0,1 a 3,1 (media 1,81 ñ 1,01) ug/ml. Ao final da primeira semana, a CVF foi de 1,38 a 3,26 (media 2,03 ñ 0,65) litros, o "VEF IND. 1" 0,85 a 1,73 (media 1,40 ñ 0,29) litros e os niveis sericos de teofilina 8,1 a 21,0 (media 13,40 ñ 4,18) ug/ml. Com a associacao teofilina e salbutamol a CVF encontra-se entre 1,24 e 2,57 (media 1,90 ñ 0,50) litros e o "VEF IND. 1" entre 0,96 e 1,90 ...

Efeitos dos agonistas beta-2-adrenergicos por via oral, sobre os niveis sericos de teofilina / Effects of adrenergic beta 2 agonists by oral route on theophylline blood levels

Diversas drogas interferem com a farmacocinetica da teofilina, acarretando variacoes de seus niveis sericos. Com o objetivo de caracterizar possiveis influencias dos beta-2-adrenergicos por via oral, na teofilinemia de pacientes em uso desta droga, analisamos dez portadores de obstrucao bronquica, com idades entre 51 a 69 (media de 59,90 ñ 6,67) anos. O estudo consistiu na analise da concentracao serica de teofilina 24 horas apos a suspensao de toda medicacao, depois de um periodo de administracao diaria isolada de 600 mg de teofilina de acao prolongada, e apos sete dias de associacao da mesma dose de teofilina com 16 mg diarios de salbutamol por via oral. As amostras sanguineas foram colhidas 4 horas apos a ingestao da dose matinal de teofilina. Os resultados obtidos foram respectivamente 2,08 ñ 1,20 ug/ml, 15,18 ñ 6,87 ug/ml e 11,45 ñ 5,15 ug/ml. Os valores da fase (teofilina isolada) foram significativamente maiores aos obtidos apos a combinacao de teofilina e salbutamol. Estes resultados permitem concluir que esta associacao por via oral interfere na farmacocinetica da teofilina. Sugerimos que nos individuos em uso destas drogas, os niveis de teofilina sejam monitorizados, para eventual correcao da dose administrada.

Farmacocinética da bupivacaína em anestesia peridural cesariana: II. Soluçöes a 0,5% com ou sem epinefrina / Pharmacokinetics of bupivacaine in epidural anesthesia for cesaren section: II. Solutions at 0,5% with of without epinephrine

A bupivacaína a 0,5% foi utilizada em anestesia peridural para cesariana na dose fixa de 150 mg, determinando-se as concentraçöes plasmáticas venosas maternas e os parâmetros farmacocinéticos do anestésico. Foram estudadas 20 gestantes de termo, submetidas à cesariana eletiva. Dez pacientes receberam 150 mg de bupivacaína a 0,5% com epinefrina 1:200.000 e 10 pacientes receberam 150 mg do mesmo anestésico sem epinefrina. As concentraçöes plasmáticas venosas de bupivacaína foram determinadas em diferentes tempos após sua injeçäo peridural, por meio de técnica em cromatografia gás-líquido. As concentraçöes plasmáticas nos diferentes tempos se mostraram sempre dentro de limites reconhecidamente seguros (valor máximo obtido 2,22 microng.ml-1), sendo sempre mais elevados no grupo que recebeu anestésico local sem epinefrina, embora essas diferenças näo tenham sido significativas. A concentraçäo plasmática máxima média foi significativamente reduzida no grupo com epinefrina (1,26 + ou - 0,20 microng.ml-1) quando comparado com o grupo sem epinefrina (1,51 + ou - 0,30 microng.ml-1); o tempo necessário para obtençäo da mesma foi coincidente nos dois grupos (20,50 + ou - 5,50 min). A quantidade total de anestésico transferida para o comportamento central e a meia vida de eliminaçäo do mesmo no grupo sem epinefrina (213,23 + ou - 76,38 microng.ml-1.min e 98,84 + ou - 40,69 min) näo foram significativamente diferentes dos obtidos no grupo com epinefrina (171,34 + ou - 52,80 microng.ml-1.min e 102,40 + ou - 35,25 min)

Farmacocinética da bupivacaína em anestesia peridural para cesariana: III. Estudo comparativo entre soluçöes a 0,5 e 0,75% / Pharmacokinetics of bupivacaine in epidural anesthesia for cesarean section. III. Comparative study of solutions at 0,5% and 0,75%

A bupivacaína a 0,5% ou 0,75% foi utilizada em anestesia peridural para cesariana na dose fixa de 150mg, determinando-se as concentraçöes plasmáticas venosas maternas e os parâmetros farmacocinéticos do anestésico. Foram estudadas 37 gestantes de termo, submetidas a cesariana eletiva, que receberam soluçöes de bupivacaína a 0,5% ou a 0,75%, com ou sem epinefrina 1:200.000. As concentraçöes plasmáticas do anestésico foram determinadas por meio de técnica em cromatografia gás-líquido. Na ausência de epinefrina, a quantidade total de droga transferida para o compartimento central e a meia vida de eliminaçäo da bupivacaína foram significativamente maiores no grupo que recebeu soluçöes a 0,75% (301,59 + ou - 80,50 microng.ml-1.min e 172,36 + ou - 33,90 min) quando comparado com o grupo que recebeu soluçöes a 0,5% (213,23 + ou - 76,38 microng.ml-1.min e 98,84 + ou - 40,69 min) (p<0,05) Na presença de epinefrina, näo se observaram diferenças significativas nas concentraçöes plasmáticas e nos parâmetros farmacocinéticos estudados, independente da utilizaçäo de soluçöes a 0,5% ou a 0,75%. A maior concentraçäo plasmática obtida em toda a investigaçäo foi de 2,22 microng.ml-1, após a utilizaçäo de bupivacaína a 0,5% sem epinefrina